SiBone (NASDAQ:SIBN) Stock: Insider Anshul Maheshwari Sells 3,247 Shares

SiBone (NASDAQ:SIBN) insider Anshul Maheshwari sold 3,247 shares of SiBone stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $25.00, for a total transaction of $81,175.00. Following the completion of the sale, the insider directly owned 211,250 shares in the company, valued at $5,281,250. This represents a 1.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Thursday, October 29th, Anshul Maheshwari sold 3,738 shares of SiBone stock. The shares were sold at an average price of $22.50, for a total value of $84,105.00.
• On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The stock was sold at an average price of $19.50, for a total transaction of $33,754.50.
• On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The stock was sold at an average price of $18.18, for a total transaction of $60,321.24.
• On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The stock was sold at an average price of $20.11, for a total value of $233,999.96.
• On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total transaction of $224,784.56.
• On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The stock was sold at an average price of $19.55, for a total transaction of $112,353.85.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The stock was sold at an average price of $18.65, for a total transaction of $87,002.25.

SiBone Stock Down 0.1%

SiBone stock opened at $24.24 on Friday. The company has a market capitalization of $1.09 billion, a PE ratio of -78.19 and a beta of 0.64. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.55 and a current ratio of 7.58. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $25.92. The firm has a 50 day moving average price of $19.81 and a 200 day moving average price of $16.59.

SiBone (NASDAQ:SIBN) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. SiBone had a negative return on equity of 7.57% and a negative net margin of 6.20%. The company had revenue of $55.70 million for the quarter, compared to analysts’ expectations of $55.31 million. Research analysts expect that SiBone will post -0.34 earnings per share for the current year.

Key Stories Impacting SiBone

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Quarterly results beat expectations and lifted shares. Si-Bone reported a third-quarter loss of $0.08 per share, narrower than the $0.13 loss analysts expected, while revenue of $55.7 million modestly exceeded estimates. The results were followed by a reported 8.7% stock jump. Article on SIBN’s post-earnings gain
• Positive Sentiment: Analyst support helped drive the stock to a 52-week high. TD Cowen raised its price target to $23 from $20, and UBS raised its target to $26 from $25; both maintained Buy ratings. SIBN reached a 52-week high amid the favorable coverage and earnings momentum. Article on SIBN’s 52-week high and analyst upgrade TD Cowen price-target article UBS price-target article
• Neutral Sentiment: Full-year revenue guidance was reaffirmed. Si-Bone’s 2026 revenue outlook of $231 million to $233 million was broadly in line with analyst expectations, offering limited new information for investors. Si-Bone Q3 results and guidance
• Negative Sentiment: Multiple insiders sold shares. CEO Laura Francis sold 75,000 shares, SVP Michael Pisetsky sold 36,241, Anshul Maheshwari sold 3,247, and director Jeffrey Dunn sold 20,000. The sales may weigh on sentiment, although each retained shares after the transactions. CEO sale filing SVP sale filing Maheshwari sale filing Dunn sale filing

Hedge Funds Weigh In On SiBone

Several hedge funds and other institutional investors have recently made changes to their positions in SIBN. First Light Asset Management LLC grew its position in shares of SiBone by 51.8% during the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock worth $132,649,000 after buying an additional 2,774,795 shares in the last quarter. Granahan Investment Management LLC lifted its stake in SiBone by 97.6% in the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after acquiring an additional 858,942 shares during the last quarter. Paradigm Capital Management Inc. NY lifted its stake in SiBone by 113.3% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock worth $14,228,000 after acquiring an additional 598,300 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in SiBone by 41.8% in the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock worth $7,816,000 after acquiring an additional 182,465 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in SiBone by 101.6% during the 1st quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock worth $5,969,000 after acquiring an additional 238,219 shares in the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on SIBN shares. Wall Street Zen raised shares of SiBone from a “hold” rating to a “buy” rating in a research report on Saturday. UBS Group lifted their price objective on shares of SiBone from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 3rd. Truist Financial upped their target price on shares of SiBone from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Finally, TD Cowen increased their target price on shares of SiBone from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Tuesday, November 3rd. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $25.00.

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.